Mutation of the PIK3CA oncogene in human cancers
Open accessAbstract
It is now well established that cancer is a genetic disease and that somatic mutations of oncogenes and tumour suppressor genes are the initiators of the carcinogenic process. The phosphatidylinositol 3-kinase signalling pathway has previously been implicated in tumorigenesis, and evidence over the past year suggests a pivotal role for the phosphatidylinositol 3-kinase catalytic subunit, PIK3CA, in human cancers. In this review, we analyse recent reports describing PIK3CA mutations in a variety of human malignancies, and discuss their possible implications for diagnosis and therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activating mutations of PIK3CA are found in 10-20% of colorectal cancers.
“Activating mutations of PIK3CA (encoding p110α) have been found in 10–20 % of CRCs [20, 68-70]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Garcia-Pedrero, J. M., García‐Carracedo, D., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & González, M. V. (2004) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235 · see citing works
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,041 · see citing works
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · see citing works
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237 · see citing works
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448 · see citing works
Oncogenes and signal transduction
Cantley, L. C., Auger, K. R., Carpenter, C. F., Duckworth, B. C., Graziani, A., Kapeller, R., & Soltoff, S. P. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,697 · see citing works
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,183 · see citing works
Fruman, D. A., Meyers, R., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,261 · see citing works
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J. F., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204 · see citing works
Detection and quantification of mutations in the plasma of patients with colorectal tumors
Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507904102 · Cited by 1,188 · see citing works
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R. A., Godfrey, T. E., Collins, C. C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,158 · see citing works
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 917 · see citing works
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915 · see citing works
Saal, L. H., Holm, K., Maurer, M. S., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., MANSUKHANI, M. M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 877 · see citing works
Dressman, D. C., Yan, H., Traverso, G., Kinzler, K. W., & Vogelstein, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133470100 · Cited by 845 · see citing works
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 827 · see citing works
The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665 · see citing works
Self-citationMutations in a signalling pathway
Parsons, D. W., Wang, T., Samuels, Y., Bardelli, A., Cummins, J. M., Wood, L. D., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599 · see citing works
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
Lee, J. W., Soung, Y. H., Kim, S. Y., Lee, H. W., Park, W. S., Nam, S. W., Kim, S. H., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2004) · Oncogene · doi:10.1038/sj.onc.1208304 · Cited by 508 · see citing works
PIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S., Lin, Y., Lung, J.-C., Chang, T.-C., Whang‐Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434 · see citing works
Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers
Levine, D. A., Bogomolniy, F., Yee, C. J., Lash, A., Barakat, R. R., Borgen, P. I., & Boyd, J. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2142 · Cited by 423 · see citing works
Functional Analysis of PIK3CA Gene Mutations in Human Colorectal Cancer
Ikenoue, T., Kanai, F., Hikiba, Y., Obata, T., Tanaka, Y., Imamura, J., Ohta, M., Jazag, A., Guleng, B., Tateishi, K., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4114 · Cited by 366 · see citing works
The prevalence of PIK3CA mutations in gastric and colon cancer
Velho, S., Oliveíra, C., Ferreira, A. M., Ferreira, A. C., Suriano, G., Schwartz, S., Duval, A., Carneiro, F., Machado, J. C., Hamelin, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.022 · Cited by 340 · see citing works
Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D., & Yan, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1170 · Cited by 336 · see citing works
Somatic mutation and gain of copy number of PIK3CA in human breast cancer
Wu, G., Xing, M., Mambo, E., Huang, X., Liu, J., Guo, Z., Chatterjee, A., Goldenberg, D., Gollin, S. M., Sukumar, S. V., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1262 · Cited by 228 · see citing works
Phosphoinositide 3-kinase in disease: timing, location, and scaffolding
Wymann, M. P., & Marone, R. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.02.011 · Cited by 212 · see citing works
Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors
Wu, G., Mambo, E., Guo, Z., Hu, S., Huang, X., Gollin, S. M., Trink, B., Ladenson, P. W., Sidransky, D., & Xing, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2281 · Cited by 190 · see citing works
Colleoni, M. A., Rotmensz, N., Peruzzotti, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.094 · Cited by 169 · see citing works
Mutations of PIK3CAin gastric adenocarcinoma
Li, V. S. W., Wong, C. W., Chan, T. L., Chan, A. S. W., Zhao, W., Chu, K., So, S. K., Chen, X., Yuen, S. T., & Leung, S. Y. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-29 · Cited by 164 · see citing works
Genetic Alterations of Phosphoinositide 3‐kinase Subunit Genes in Human Glioblastomas
Mizoguchi, M., Nutt, C. L., Mohapatra, G., & Louis, D. N. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00080.x · Cited by 135 · see citing works
Volinia, S., Hiles, I. D., Ormondroyd, E., Nižetić, D., Antonacci, R., Rocchi, M., & Waterfield, M. D. (1994) · Genomics · doi:10.1006/geno.1994.1655 · Cited by 93 · see citing works
The prognostic significance of axillary lymph-node micrometastases in breast cancer patients
Kuijt, G. P., Voogd, A. C., van de Poll-Franse, L. V., et al. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.01.001 · Cited by 74 · see citing works
The clinical significance of axillary lymph node micrometastases in breast cancer
Sakorafas, G. H., Geraghty, J., & Pavlakis, G. (2004) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2004.06.020 · Cited by 45 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
RAS Interaction with PI3K: More Than Just Another Effector Pathway
Castellano, E., & Downward, J. (2011) · Genes & Cancer · doi:10.1177/1947601911408079 · Cited by 762 · see citing works
Prenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291 · see citing works
Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007287 · Cited by 259 · see citing works
Hoeflich, K. P., Merchant, M., Orr, C., Chan, J., Den Otter, D., Berry, L., Kasman, I., Koeppen, H., Rice, K., Yang, N.-Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1515 · Cited by 242 · see citing works
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216 · see citing works
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123 · see citing works
Chakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S., Engelman, J. A., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.257 · Cited by 102 · see citing works
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87 · see citing works
Comprehensive pharmacogenomic characterization of gastric cancer
Sa, J. K., Hong, J. Y., Lee, I.-K., Kim, J.-S., Sim, M.-H., Kim, H. J., An, J. Y., Sohn, T. S., Lee, J. H., Bae, J. M., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-0717-8 · Cited by 46 · see citing works
Dynamic Protein Allosteric Regulation and Disease
Nussinov, R., Tsai, C.-J., & Jang, H. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-8719-7_2 · Cited by 18 · see citing works
- Authors
- Karakas, B., Bachman, K. E., & Park, B. H.
- Affiliations
- Johns Hopkins University (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Park, B H
- Venue
- British Journal of Cancer
- Published
- 2006-01-31
- Volume
- 94
- Issue
- 4
- Pages
- 455-459
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361173
- OpenAlex
- W1971843650
- Cited by
- 505
- References
- 36
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 28 · 2023: 23 · 2022: 23 · 2021: 25 · 2020: 24 · 2019: 27 · 2018: 39 · 2017: 30 · 2016: 42 · 2015: 21 · 2014: 22 · 2013: 27 · 2012: 30
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- American Cancer Society (IRG-58-005-41)
- Avon Foundation for Women
- V Foundation for Cancer Research
- Flight Attendant Medical Research Institute
- Entertainment Industry Foundation
- National Institutes of Health (CA88843)
- National Cancer Institute (P50-CA-88843, P50CA088843)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- PIK3CA, phosphatidylinositol 3-kinase, oncogenic mutations, carcinogenesis, cancer genetics, PI3K signaling, somatic mutations, cancer diagnosis, cancer therapy
- MeSH terms
- Humans, Mutation, Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
